Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$25.06 ▼ -1.58
(-5.93%)
MKT CAP: $4.00B • VOL: 2.34M
52W L $12 52W H $31
ADPT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $277.0M | $179.0M | $170.3M |
| YoY Revenue Growth % | +54.8% | +5.1% | — |
| Gross Profit | $205.6M | $106.9M | — |
| Gross Margin % | 74.2% | 59.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$57.1M | -$162.5M | -$227.0M |
| Operating Margin % | -20.6% | -90.8% | -133.3% |
| Net Income (GAAP) | -$59.5M | -$159.5M | -$225.3M |
| EBITDA (Normalized) | -$54.8M | -$159.6M | -$220.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$46.0M | -$95.2M | -$156.3M |
| Capital Expenditures (CapEx) | $3.0M | $3.7M | $7.7M |
| Free Cash Flow (FCF) | -$48.9M | -$98.9M | -$164.0M |
| FCF Margin % | -17.7% | -55.3% | -96.3% |
| Return on Invested Capital (ROIC %) | -16.4% | -44.7% | -12.0% |
| Cash & Short-Term Equivalents | $70.5M | $47.9M | — |
| Total Debt (Short + Long Term) | $126.6M | $132.4M | $578.6M |
| Total Stockholders' Equity | $218.8M | $202.7M | $1.19B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ADPT.